- Home
- ALCE vs VIRX Comparison
ALCE vs VIRX Comparison
Compare ALCE & VIRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALCE
- VIRX
- Stock Information
- Founded
- ALCE 2019
- VIRX 2007
- Country
- ALCE United States
- VIRX United States
- Employees
- ALCE N/A
- VIRX N/A
- Industry
- ALCE Power Generation
- VIRX Biotechnology: Pharmaceutical Preparations
- Sector
- ALCE Utilities
- VIRX Health Care
- Exchange
- ALCE Nasdaq
- VIRX Nasdaq
- Market Cap
- ALCE 8.6M
- VIRX 7.7M
- IPO Year
- ALCE N/A
- VIRX N/A
- Fundamental
- Price
- ALCE $1.75
- VIRX $0.15
- Analyst Decision
- ALCE
- VIRX Buy
- Analyst Count
- ALCE 0
- VIRX 4
- Target Price
- ALCE N/A
- VIRX $5.00
- AVG Volume (30 Days)
- ALCE 208.7K
- VIRX 2.7M
- Earning Date
- ALCE 11-26-2024
- VIRX 11-13-2024
- Dividend Yield
- ALCE N/A
- VIRX N/A
- EPS Growth
- ALCE N/A
- VIRX N/A
- EPS
- ALCE N/A
- VIRX N/A
- Revenue
- ALCE N/A
- VIRX N/A
- Revenue This Year
- ALCE N/A
- VIRX N/A
- Revenue Next Year
- ALCE N/A
- VIRX N/A
- P/E Ratio
- ALCE N/A
- VIRX N/A
- Revenue Growth
- ALCE N/A
- VIRX N/A
- 52 Week Low
- ALCE $1.64
- VIRX $0.13
- 52 Week High
- ALCE $272.25
- VIRX $1.31
- Technical
- Relative Strength Index (RSI)
- ALCE 25.53
- VIRX 22.07
- Support Level
- ALCE $1.71
- VIRX $0.17
- Resistance Level
- ALCE $2.20
- VIRX $0.21
- Average True Range (ATR)
- ALCE 0.28
- VIRX 0.02
- MACD
- ALCE 0.00
- VIRX -0.00
- Stochastic Oscillator
- ALCE 9.43
- VIRX 19.80
About ALCE Alternus Clean Energy Inc.
Alternus Clean Energy Inc is an international independent clean energy producer. It develops, installs, owns and operates a diverse portfolio of utility-scale solar photovoltaic power stations (PV parks) in Europe and the USA as a long-term owner. The solar parks benefit from long-term government offtake contracts and/or Power Purchase Agreements (PPAs) with investment grade off-takers, plus energy sales to local power grids. It has approximately 8 operating parks, a total of 44 MWp in operation.
About VIRX Viracta Therapeutics Inc.
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.